CONNECT WITH US
HealthTech

HealthTech

Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial

Medical Xpress logo

Published on

Add as a preferred source on Google
Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was associated with improvements in inflammatory skin conditions, while opening new avenues for research on brain health and Alzheimer's disease.

The phase 2 clinical trial of tofacitinib, a medication known as a JAK inhibitor that blocks certain signals involved in immune responses and inflammation, was published in Cell Reports Medicine.

The findings provide important evidence that targeting underlying immune dysregulation may offer a new approach to addressing multiple health conditions associated with Down syndrome.

Down syndrome is caused by an extra copy of chromosome 21, which carries genes encoding several receptors for interferons, molecules that regulate immune responses. Previous research by the Crnic Institute established that this genetic change contributes to chronically elevated interferon signaling and widespread immune dysregulation. The new study tested whether reducing this excessive signaling could be a viable therapeutic approach.

The research team enrolled adolescents and adults with Down syndrome who also had inflammatory skin conditions, such as hidradenitis suppurativa and alopecia areata. Participants received tofacitinib twice daily for 16 weeks, with an optional extension to 40 weeks. The trial included extensive safety monitoring, dermatological evaluations, blood-based molecular analyses and neuropsychological assessments.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.